GB0502250D0 - Use - Google Patents

Use

Info

Publication number
GB0502250D0
GB0502250D0 GBGB0502250.4A GB0502250A GB0502250D0 GB 0502250 D0 GB0502250 D0 GB 0502250D0 GB 0502250 A GB0502250 A GB 0502250A GB 0502250 D0 GB0502250 D0 GB 0502250D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0502250.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IC Vec Ltd
Original Assignee
IC Vec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IC Vec Ltd filed Critical IC Vec Ltd
Priority to GBGB0502250.4A priority Critical patent/GB0502250D0/en
Publication of GB0502250D0 publication Critical patent/GB0502250D0/en
Priority to JP2007553689A priority patent/JP2008528665A/ja
Priority to EP06704231A priority patent/EP1846004A1/en
Priority to PCT/GB2006/000343 priority patent/WO2006082397A1/en
Priority to US11/883,661 priority patent/US20080319184A1/en
Priority to AU2006210715A priority patent/AU2006210715A1/en
Priority to CNA2006800090694A priority patent/CN101180066A/zh
Priority to CA002596959A priority patent/CA2596959A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
GBGB0502250.4A 2005-02-03 2005-02-03 Use Ceased GB0502250D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0502250.4A GB0502250D0 (en) 2005-02-03 2005-02-03 Use
JP2007553689A JP2008528665A (ja) 2005-02-03 2006-02-01 ジヌクレオチドポリリン酸誘導体の使用法
EP06704231A EP1846004A1 (en) 2005-02-03 2006-02-01 New uses of dinucleotide polyphosphate derivatives
PCT/GB2006/000343 WO2006082397A1 (en) 2005-02-03 2006-02-01 New uses of dinucleotide polyphosphate derivatives
US11/883,661 US20080319184A1 (en) 2005-02-03 2006-02-01 Uses of Dinucleotide Polyphosphate Derivatives
AU2006210715A AU2006210715A1 (en) 2005-02-03 2006-02-01 New uses of dinucleotide polyphosphate derivatives
CNA2006800090694A CN101180066A (zh) 2005-02-03 2006-02-01 二核苷多磷酸衍生物的新应用
CA002596959A CA2596959A1 (en) 2005-02-03 2006-02-01 New uses of dinucleotide polyphosphate derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0502250.4A GB0502250D0 (en) 2005-02-03 2005-02-03 Use

Publications (1)

Publication Number Publication Date
GB0502250D0 true GB0502250D0 (en) 2005-03-09

Family

ID=34307930

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0502250.4A Ceased GB0502250D0 (en) 2005-02-03 2005-02-03 Use

Country Status (8)

Country Link
US (1) US20080319184A1 (enExample)
EP (1) EP1846004A1 (enExample)
JP (1) JP2008528665A (enExample)
CN (1) CN101180066A (enExample)
AU (1) AU2006210715A1 (enExample)
CA (1) CA2596959A1 (enExample)
GB (1) GB0502250D0 (enExample)
WO (1) WO2006082397A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201209244D0 (en) * 2012-05-25 2012-07-04 Globalacorn Ltd Compositions
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
GB201320959D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
KR102504764B1 (ko) * 2017-06-21 2023-03-02 주식회사 종근당 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
WO2021123388A1 (en) * 2019-12-20 2021-06-24 Nuvamid Sa Novel nicotinamide di-nucleotide derivatives and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5681823A (en) * 1996-05-02 1997-10-28 Prp Inc. P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
ES2264197T3 (es) * 1997-02-06 2006-12-16 Inspire Pharmaceuticals, Inc. Dinucleotidos y sus usos.
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
GB9711848D0 (en) * 1997-06-06 1997-08-06 William Harvey Research Limite Treatment and prophylaxis of infraction
WO1999003480A1 (en) * 1997-07-17 1999-01-28 William Harvey Research Limited Use of adenosine tri- or tetra-phosphates and their analogues for the treatment of cerebral infarction
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
GB2394419B (en) * 2001-06-25 2005-09-07 Inspire Pharmaceuticals Inc Joint lubrication with p2y purinergic receptor agonists
CN1612739A (zh) * 2001-11-06 2005-05-04 印斯拜尔药品股份有限公司 治疗或预防炎性疾病的方法
US7203743B2 (en) * 2001-12-28 2007-04-10 Nortel Networks Limited Hierarchical tree-based protection scheme for mesh networks

Also Published As

Publication number Publication date
WO2006082397A1 (en) 2006-08-10
AU2006210715A1 (en) 2006-08-10
CN101180066A (zh) 2008-05-14
EP1846004A1 (en) 2007-10-24
JP2008528665A (ja) 2008-07-31
CA2596959A1 (en) 2006-08-10
US20080319184A1 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
GB0522715D0 (en) New use
GB0505954D0 (en) Novel use
DE502005007477D1 (en) Delta-sigma-modulator
GB0511190D0 (en) Use
GB0520176D0 (en) Use
GB0506001D0 (en) Novel use
GB0526031D0 (en) Use
GB0502250D0 (en) Use
GB0526552D0 (en) New use
GB0526032D0 (en) Use
EP1846443A4 (en) NEW USE
DE502006002219D1 (en) Rotationspumpe
DE502006007734D1 (en) Thiazolcarbonsäureanilide
DE502006004337D1 (en) Strangführungsrolle
GB0508924D0 (en) New use
GB0503950D0 (en) Use
GB0507986D0 (en) Use
GB0507874D0 (en) Use
GB0503949D0 (en) Use
AU3292P (en) DP303 Dianella prunina
AU4036P (en) Dottie Calathea roseo-picta
AU3621P (en) Scacover Scaevola aemula
AU3401P (en) Archise Arctotis fastuosa
AU3393P (en) Breakwell xTriticosecale
GB0515817D0 (en) New use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)